Short Message Service (SMS) Reminders for Stroke Secondary Preventative Medications
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02336412 |
Recruitment Status :
Completed
First Posted : January 13, 2015
Last Update Posted : February 1, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stroke Ischemic Attack, Transient | Other: SMS reminder | Not Applicable |
We aim to recruit adult patients diagnosed with stroke or transient ischaemic attack (TIA) who were prescribed secondary preventative medication and are living in the community. They will be provided with a patient information sheet (PIS) with details on the study and will be contacted later to ask if they wish to take part. If so, an arrangement will be made for them to attend a clinic review where they will sign the consent form. Immediately then participants who consent will be randomized into control (will receive education and motivation interviews but not text messages to remind them) or intervention (will receive education and motivation interviews and will be sent a daily text message to remind them of taking their medication). Baseline assessment will include medical history and medications prescribed. They will be given detailed information on their specific prescribed medication and will be handed booklets with relevant information. They will be asked to answer a medication adherence questionnaire and will be given a medication diary to fill in at home. All participants will receive ambulatory blood pressure monitoring.
Cholesterol measurement will be made using a finger prick monitor. Participants in the intervention group will be informed that they will receive a daily text message in the morning to remind them about their medications.
Follow-up visits will take place after 1 and 3 months in which the same checks will be carried out as at the baseline visit. At 1 month, the cholesterol level and ambulatory blood pressure level will be repeated. Participants will be encouraged to ask if they have any concerns regarding their medications. At the end of the second visit, participants will be asked if they are satisfied with the care they received during the visits as a quality assessment.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 10 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | The Use of Short Message Service (SMS) as a Reminder for Continuation of Treatment With Secondary Preventative Medications After Stroke or TIA |
Study Start Date : | January 2015 |
Actual Primary Completion Date : | October 2015 |
Actual Study Completion Date : | October 2015 |
Arm | Intervention/treatment |
---|---|
Experimental: SMS reminder
Daily SMS medication reminder
|
Other: SMS reminder
Daily SMS medication reminder |
No Intervention: No SMS reminder
No daily SMS medication reminder
|
- Adherence rate to stroke secondary preventative medication [ Time Frame: 3 months ]Morisky Medication Adherence Scale (MMAS) - 8 items
- Effect of medication adherence on clinical outcomes [ Time Frame: 3 months ]Number of participants reaching target blood pressure level
- Effect of medication adherence on clinical outcomes [ Time Frame: 3 months ]Number of participants reaching target cholesterol level

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- diagnosed with stroke or TIA
- treated with any combination of anti-platelet, antihypertensive, and/or lipid-modifying drugs; at least one of which started over the past month
- living in the community
Exclusion Criteria:
- severe disability (modified Rankin Scale (mRS) ≥ 4)
- patients unable to consent
- patients with no facility to be reminded by SMS or voicemail message

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02336412
United Kingdom | |
Western Infirmary, NHS Greater Glasgow and Clyde | |
Glasgow, United Kingdom, G11 6NT |
Study Director: | Jesse Dawson, BSc MBChB MD | University of Glasgow |
Responsible Party: | NHS Greater Glasgow and Clyde |
ClinicalTrials.gov Identifier: | NCT02336412 |
Other Study ID Numbers: |
GN14NE625 |
First Posted: | January 13, 2015 Key Record Dates |
Last Update Posted: | February 1, 2016 |
Last Verified: | January 2016 |
Medication adherence |
Stroke Ischemic Attack, Transient Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Vascular Diseases Cardiovascular Diseases Brain Ischemia |